IGM BIOSCIENCES INC (IGMS) Fundamental Analysis & Valuation

NASDAQ:IGMS • US4495851085

1.27 USD
-0.03 (-2.31%)
At close: Aug 13, 2025
1.28 USD
+0.01 (+0.79%)
After Hours: 8/13/2025, 8:15:46 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This IGMS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Taking everything into account, IGMS scores 3 out of 10 in our fundamental rating. IGMS was compared to 519 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for IGMS as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, IGMS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

2

1. IGMS Profitability Analysis

1.1 Basic Checks

  • IGMS had negative earnings in the past year.
  • In the past year IGMS has reported a negative cash flow from operations.
  • In the past 5 years IGMS always reported negative net income.
  • In the past 5 years IGMS always reported negative operating cash flow.
IGMS Yearly Net Income VS EBIT VS OCF VS FCFIGMS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

  • With a Return On Assets value of -49.53%, IGMS perfoms like the industry average, outperforming 51.00% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -52.48%, IGMS is in the better half of the industry, outperforming 64.85% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 7.99%, IGMS belongs to the top of the industry, outperforming 93.26% of the companies in the same industry.
Industry RankSector Rank
ROA -49.53%
ROE -52.48%
ROIC 7.99%
ROA(3y)-58.3%
ROA(5y)-50.04%
ROE(3y)-202.16%
ROE(5y)-139.04%
ROIC(3y)N/A
ROIC(5y)N/A
IGMS Yearly ROA, ROE, ROICIGMS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

1.3 Margins

  • Looking at the Operating Margin, with a value of 7.04%, IGMS belongs to the top of the industry, outperforming 91.62% of the companies in the same industry.
  • The Profit Margin and Gross Margin are not available for IGMS so they could not be analyzed.
Industry RankSector Rank
OM 7.04%
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IGMS Yearly Profit, Operating, Gross MarginsIGMS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. IGMS Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so IGMS is destroying value.
  • Compared to 1 year ago, IGMS has more shares outstanding
  • The number of shares outstanding for IGMS has been increased compared to 5 years ago.
  • There is no outstanding debt for IGMS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IGMS Yearly Shares OutstandingIGMS Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
IGMS Yearly Total Debt VS Total AssetsIGMS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • Based on the Altman-Z score of -2.33, we must say that IGMS is in the distress zone and has some risk of bankruptcy.
  • IGMS's Altman-Z score of -2.33 is in line compared to the rest of the industry. IGMS outperforms 50.09% of its industry peers.
  • There is no outstanding debt for IGMS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.33
ROIC/WACC0.82
WACC9.76%
IGMS Yearly LT Debt VS Equity VS FCFIGMS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M 300M

2.3 Liquidity

  • IGMS has a Current Ratio of 17.66. This indicates that IGMS is financially healthy and has no problem in meeting its short term obligations.
  • IGMS has a Current ratio of 17.66. This is amongst the best in the industry. IGMS outperforms 92.71% of its industry peers.
  • A Quick Ratio of 17.66 indicates that IGMS has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 17.66, IGMS belongs to the top of the industry, outperforming 92.71% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 17.66
Quick Ratio 17.66
IGMS Yearly Current Assets VS Current LiabilitesIGMS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. IGMS Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 85.01% over the past year.
  • IGMS shows a strong growth in Revenue. In the last year, the Revenue has grown by 4881.11%.
EPS 1Y (TTM)85.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%300%
Revenue 1Y (TTM)4881.11%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11353.19%

3.2 Future

  • The Earnings Per Share is expected to grow by 11.78% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 18.08% on average over the next years. This is quite good.
EPS Next Y59.87%
EPS Next 2Y27.79%
EPS Next 3Y19.3%
EPS Next 5Y11.78%
Revenue Next Year249.45%
Revenue Next 2Y126.25%
Revenue Next 3Y73.98%
Revenue Next 5Y18.08%

3.3 Evolution

IGMS Yearly Revenue VS EstimatesIGMS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5M 10M
IGMS Yearly EPS VS EstimatesIGMS Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -1 -2 -3 -4 -5

More info and screens

Find the best growth stocksShow best growing peers

0

4. IGMS Valuation Analysis

4.1 Price/Earnings Ratio

  • IGMS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IGMS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IGMS Price Earnings VS Forward Price EarningsIGMS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -5.77
IGMS Per share dataIGMS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

  • IGMS's earnings are expected to grow with 19.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.79%
EPS Next 3Y19.3%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IGMS Dividend Analysis

5.1 Amount

  • IGMS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

IGMS Fundamentals: All Metrics, Ratios and Statistics

IGM BIOSCIENCES INC

NASDAQ:IGMS (8/13/2025, 8:15:46 PM)

After market: 1.28 +0.01 (+0.79%)

1.27

-0.03 (-2.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-31
Earnings (Next)11-06
Inst Owners53.06%
Inst Owner Change-100%
Ins Owners2.48%
Ins Owner Change0%
Market Cap76.57M
Revenue(TTM)145.05M
Net Income(TTM)-53.00M
Analysts48.89
Price Target1.27 (0%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)297.19%
Min EPS beat(2)-21.95%
Max EPS beat(2)616.34%
EPS beat(4)2
Avg EPS beat(4)147.4%
Min EPS beat(4)-23.77%
Max EPS beat(4)616.34%
EPS beat(8)5
Avg EPS beat(8)-167.29%
EPS beat(12)9
Avg EPS beat(12)-109.67%
EPS beat(16)12
Avg EPS beat(16)-83.61%
Revenue beat(2)1
Avg Revenue beat(2)2105.97%
Min Revenue beat(2)-84.23%
Max Revenue beat(2)4296.17%
Revenue beat(4)3
Avg Revenue beat(4)1075.96%
Min Revenue beat(4)-84.23%
Max Revenue beat(4)4296.17%
Revenue beat(8)3
Avg Revenue beat(8)515.32%
Revenue beat(12)5
Avg Revenue beat(12)338.08%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-33.33%
EPS NQ rev (1m)37.73%
EPS NQ rev (3m)-16%
EPS NY rev (1m)0%
EPS NY rev (3m)-20.2%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.27%
Revenue NY rev (1m)0%
Revenue NY rev (3m)57.03%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.53
P/FCF N/A
P/OCF N/A
P/B 0.76
P/tB 0.76
EV/EBITDA -5.77
EPS(TTM)-0.55
EYN/A
EPS(NY)-1.19
Fwd EYN/A
FCF(TTM)-2.62
FCFYN/A
OCF(TTM)-2.59
OCFYN/A
SpS2.41
BVpS1.67
TBVpS1.67
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -49.53%
ROE -52.48%
ROCE 10.11%
ROIC 7.99%
ROICexc N/A
ROICexgc N/A
OM 7.04%
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-58.3%
ROA(5y)-50.04%
ROE(3y)-202.16%
ROE(5y)-139.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover1.36
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 29.58%
Cap/Sales 1.5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.66
Quick Ratio 17.66
Altman-Z -2.33
F-Score5
WACC9.76%
ROIC/WACC0.82
Cap/Depr(3y)125.69%
Cap/Depr(5y)474.33%
Cap/Sales(3y)578.65%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)85.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%300%
EPS Next Y59.87%
EPS Next 2Y27.79%
EPS Next 3Y19.3%
EPS Next 5Y11.78%
Revenue 1Y (TTM)4881.11%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11353.19%
Revenue Next Year249.45%
Revenue Next 2Y126.25%
Revenue Next 3Y73.98%
Revenue Next 5Y18.08%
EBIT growth 1Y104.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year61.17%
EBIT Next 3Y22.7%
EBIT Next 5YN/A
FCF growth 1Y19.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.46%
OCF growth 3YN/A
OCF growth 5YN/A

IGM BIOSCIENCES INC / IGMS FAQ

Can you provide the ChartMill fundamental rating for IGM BIOSCIENCES INC?

ChartMill assigns a fundamental rating of 3 / 10 to IGMS.


Can you provide the valuation status for IGM BIOSCIENCES INC?

ChartMill assigns a valuation rating of 0 / 10 to IGM BIOSCIENCES INC (IGMS). This can be considered as Overvalued.


How profitable is IGM BIOSCIENCES INC (IGMS) stock?

IGM BIOSCIENCES INC (IGMS) has a profitability rating of 2 / 10.


Can you provide the financial health for IGMS stock?

The financial health rating of IGM BIOSCIENCES INC (IGMS) is 7 / 10.